Navigation Links
Cedars-Sinai Medical Center opens patient trial of virus that attacks brain cancer cells

LOS ANGELES (April 15, 2008) A common, naturally occurring virus that attacks cancer cells but appears to be harmless to normal cells is being studied as a possible treatment for malignant, highly aggressive and deadly brain tumors called gliomas. Researchers at Cedars-Sinai Medical Center are among a few in the United States evaluating this experimental therapy.

Over the course of a lifetime, most adults will be exposed to the virus in its natural state. It commonly infects the lungs and intestines but unlike most viruses causes few if any symptoms and is usually eliminated by the body within two weeks. But while the reovirus (respiratory enteric orphan virus) may be harmless to normal cells, it can specifically kill certain cancer cells.

Vulnerable cancer cells have a defect in a signaling pathway (the Ras pathway) that controls key cell functions. The reovirus is able to infect and kill cancer cells that have an activated Ras pathway, but the virus does not normally come into contact with cancer cells. Researchers at Oncolytics Biotech Inc., of Calgary, Canada, developed a therapeutic drug, REOLYSIN, from the reovirus and are conducting multicenter clinical trials for a variety of cancers. Cedars-Sinai is participating only in the study on recurrent gliomas, the most common and deadly brain cancers.

Based on the fact that many types of cancer cells have an activated Ras pathway, the company estimates that up to two thirds of all human cancers are susceptible to reovirus induced cell death .

Although not every glioma cell line has an activated Ras pathway, Ras activation is very common in these malignant brain cancers. In lab tests and animal studies, the reovirus appears to target Ras-activated tumor cells and leave normal cells alone, said neurosurgeon John S. Yu, M.D., director of Surgical Neuro-oncology at Cedars-Sinais Department of Neurosurgery. Yu is principal investigator of the REOLYSIN clinical trial at Cedars-Sinai.

According to the protocol of this open-label Phase I and II trial, patients will receive a single treatment of REOLYSIN, infused over 72 hours and directed into the tumor under sophisticated guidance. Expected length of hospital stay is about five days, and patients progress will be followed for at least 12 weeks.

Oncolytics published results of preclinical studies in the June 20, 2001 issue of the Journal of the National Cancer Institute. In an animal study, mice with gliomas that were treated with a single injection of reovirus survived significantly longer than untreated mice. Complete tumor regression was found in 20 of 23 mice treated with the virus.

In laboratory studies, widespread cell killing was seen in 19 of 24 established human glioma cell lines tested. Reovirus also infected and killed all nine of nine primary glioma cultures taken from brain tumor surgical specimens. Primary refers to gliomas originating in the brain, not metastasizing from other locations.


Contact: Sandy Van
Cedars-Sinai Medical Center

Related medicine news :

1. China Sky One Medical, Inc. Announces Its Successful Participation in the 20th International Medical Instruments and Equipment Exhibition
2. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Inverness Medical Innovations, Inc. Who Invested in the Inverness Medical Innovations, Inc. Employee Savings Plan
3. Roseland Medical Center Hosts Recognition Ceremony and Open House
4. Golden State Medical Supply Selects IBM Technology to Comply With California Prescription Drug Pedigree Regulations
5. Top Policy Experts to Debate Link Between Rising Health Care Costs and Advances in Medical Technology, Wednesday, April 16, 2008, From 8:30 - 10:00 A.M., at DCs National Press Club
6. Health Care Workforce Experts Available to Comment on IOM Report on Aging Baby Boomers and Impending Medical System Crisis
7. HHS Names First Director of the Biomedical Advanced Research Development Authority
8. Northwest Hospital & Medical Center Hosts Health & Wellness Pavilion At Second Annual King 5 Healthy Living Expo
9. VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
10. Greenway Medical Technologies Experiences Continued Growth in OB/GYN Marketplace
11. Medical Records Institute (MRI) Develops Initiative for EMRs Supporting Medicolegal Requirements
Post Your Comments:
(Date:11/27/2015)... ... 27, 2015 , ... A simply groundbreaking television series, "Voices in America", which ... into an array of issues that are presently affecting Americans. Dedicated to providing the ... show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... in central Michigan, have come together on Thanksgiving Day to share the things ... for viewing on the Serenity Point YouTube channel, patients displayed what they wrote ...
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
Breaking Medicine Technology: